RxDoctor Payments Data

James Marshall

Family Medicine · Hoover, ALNPI 1013093566

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. Reporting peaked in 2020 at $1,337 and has fallen 97.8% since, to $30 in 2023.

$2,685in general payments, 2019–2025

Across 182 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$667
  • Boehringer Ingelheim$368
  • AstraZeneca$295
  • Johnson & Johnson$255
  • AbbVie$230
  • Pfizer$226
  • plus $645 from 14 others

What the payments were for

  • Food & beverage$2,685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,685 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama →

Other family medicine in Hoover

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →